Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
31.27
+1.14 (3.78%)
At close: May 12, 2025, 4:00 PM
31.75
+0.48 (1.54%)
After-hours: May 12, 2025, 7:54 PM EDT
Alkermes Revenue
Alkermes had revenue of $306.51M in the quarter ending March 31, 2025, a decrease of -12.52%. This brings the company's revenue in the last twelve months to $1.51B, down -12.31% year-over-year. In the year 2024, Alkermes had annual revenue of $1.56B, down -6.36%.
Revenue (ttm)
$1.51B
Revenue Growth
-12.31%
P/S Ratio
3.39
Revenue / Employee
$840,983
Employees
1,800
Market Cap
5.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ALKS News
- 11 days ago - Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible - Seeking Alpha
- 11 days ago - Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Alkermes plc Reports First Quarter 2025 Financial Results - PRNewsWire
- 12 days ago - New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) - PRNewsWire
- 25 days ago - Alkermes to Report First Quarter Financial Results on May 1, 2025 - PRNewsWire
- 5 weeks ago - Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference - PRNewsWire
- 5 weeks ago - Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PRNewsWire
- 6 weeks ago - New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PRNewsWire